Kiadis plots a Euro IPO; Amicus files Fabry drug for EU approval;

@FierceBiotech: Takeda uprooting its U.S. vaccines operations, joining the R&D migration to Boston. Report | Follow @FierceBiotech

@JohnCFierce: Trending: With a crucial CAR-T trial looming for Cellectis, a confident André Choulika is laying it all on the line. More | Follow @JohnCFierce

@DamianFierce: $FOLD plans to market the Fabry drug migalastat as Galafold. Release | Follow @DamianFierce

> Dutch biotech Kiadis Pharma is planning to go public on the Amsterdam and Brussels stock exchanges, raising cash for its pipeline of cancer treatments. News

> Amicus Therapeutics ($FOLD) has submitted migalastat, a treatment for the rare Fabry disease, for European approval. The company expects to file the drug with the FDA in the second half of the year. More (PDF)

> Cellectis ($CLLS) has recruited the cancer experts at Weill Cornell Medical College to accelerate the development of its lead CAR-T candidate for acute myelogenous leukemia. Release

> Merck ($MRK) has extended its collaboration with Agenus ($AGEN), working to develop new checkpoint inhibitors for cancer. Item

Medical Device News

@FierceMedDev: Merck teams up with NanoString to find genes that predict response to Keytruda. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Ishrak plays up four-point integration plan during Medtronic's earnings call. Story | Follow @VarunSaxena2

@EmilyWFierce: LabCorp strikes liquid biopsy deal with Sysmex for cancer drug development. FierceDiagnostics article | Follow @EmilyWFierce

> FDA clears first 'smart' spirometer, enabling continuous tracking of lung function via tablet. Story

> Former Stryker R&D exec spins off new company with novel bone adhesive. Report

> Aussie startup gets $11.5M to market FDA-cleared, wearable Parkinson's disease tracker. Article

Pharma News

@FiercePharma: India's pharmacies launch pre-emptive protest to online drug sales. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: India's Wockhardt believes FDA issues at 2 key plants can be resolved sometime next year. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: It's Stanley Cup Finals day!! And I just slipped "power play" into a headline. | Follow @CarlyHFierce

> Roche unchallenged at top of cancer sellers, but Celgene could fight Novartis for No. 2. Story

> Endo plans $1.75B stock sale to help cover Par buy. Article

> Teva shops for bigger Mylan stake in deal-forcing power play. Report

Pharma Marketing News

> Eyeing Xofigo growth, Bayer launches 'speak up' campaign in prostate cancer. News

> Big Pharma grapples with idiosyncrasies of orphan drug marketing. Story

> Novo Nordisk spins cycling into diabetes awareness with pro racing team. Article

> GSK's Flonase zooms to top of allergy category after DTC push. Item

> High-profile Huntington's disease film scores on social media, but where was pharma? More

Biotech Research News

> NCI matchmaker study explores uses of targeted drugs. Item

> Circadian rhythm research spotlights a possible cancer drug target. Report

> Aging researchers at McMaster flag role of a key protein in muscle loss. More

> Regenerative med researchers advance work on recycling discarded kidneys. Article

> Northeastern team solves mystery of recurring Lyme disease, offers a solution. Story

Diagnostics News

> Roche's Ventana teams up with Halozyme for pancreatic cancer companion Dx. Story

> Invitae slashes prices for full menu of genetic tests. Item

> LabCorp strikes liquid biopsy deal with Sysmex for cancer drug development. Article

> Merck teams up with NanoString to find genes that predict response to Keytruda. Story

> France's Labco sells out to Cinven for $1.3B after abandoning IPO. Report

Suggested Articles

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.